Target Study

Target Study

TARGET is a 4,000 patient, multicenter, double-blinded, randomized, controlled, parallel-group, phase III clinical trial. The primary aim of the study is to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically ventilated patients improves 90-day survival when compared to routine care. A secondary aim is to determine if augmentation of calorie delivery using energy dense enteral nutrition in mechanically. 

Ventilated patients improved functional outcomes at 180 days when compared to routine care. BTG plc (LSE: BTG), a global specialty healthcare company, today announced plans to initiate the TheraSphere® Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment (TARGET). The study will evaluate two-compartment dosimetry (normal tissue and tumor absorbed dose) in hepatocellular carcinoma patients in interventional oncology in an effort towards a more personalized approach to 90Y radioembolization therapy for liver cancer patients. 

Study Material

Peter Pattison, BTG General Manager Interventional Oncology, commented "BTG investment in TARGET demonstrates our goal to further tailor TheraSphere® therapy to an individual patient liver, tumor, and disease characteristics. TARGET will complement other studies, and will be undertaken in collaboration with leading clinical and industry partners in this field, with the ultimate goal of improving patient outcomes in HCC." The primary endpoint of the study will determine the correlation between the normal tissue absorbed dose, based on 99mTc-MAA, and ≥Grade 3 hyperbilirubinemia for patients administered 

TheraSphere®. Secondary endpoints in the TARGET study include: tumor absorbed dose, incidence of serious adverse events, select dose related adverse events, clinical laboratory assessment, objective tumor response and overall survival. "The current one-compartment dosimetry method for TheraSphere® incorporates a target absorbed dose to the entire liver and adjusts for liver mass, however, a more individualized approach is needed to optimize dosimetry." said professor Marnix Lam, Nuclear Medicine.

Study Notes

UMC Utrecht, Netherlands. "The TARGET retrospective study will collect clinical data with the goal of outlining a two-compartment dosimetry model based on 99mTc-MAA dosimetry and customized software manufactured by Mirada Medical. The objective of the study is to provide treating physicians with clinical data that will allow a more tailored dosimetry approach for treating patients. By taking into account the absorbed dose to the tumor and normal liver, physicians will have the opportunity to better personalize 90Y radioembolization therapy."